Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR plus NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi

Abstract

Ivonescimab is a first in class bispecific antibody that cooperatively targets both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). There is clinical unmet need in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations in the relapsed/refractory setting, where subsequent management options remain limited. HARMONi is a global multicenter, randomized, double-blinded, placebo-controlled, Phase 3 study evaluating the efficacy and safety of adding ivonescimab to chemotherapy for patients whose disease has progressed on 3rd generation EGFR-TKI.